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Abstract:  Lactoferrin (LF), a multifunctional molecule present in human secretions, has potent inhibitory activities 
against human immunodeficiency virus (HIV). The aim of the study was to evaluate whether human LF (hLF) and its 
exposed domain LF-33 represented by the peptide (LF-33-GRRRRSVQWCAVSQPEATKCFQWQRNMRKVRGP) 
involved in LF-HIV gag binding and endotoxines neutralization, may inhibit early steps of HIV mucosal transmission. 
Human LF and the peptide LF-33 inhibited the attachment of primary X4-tropic HIV-1NDK and R5-tropic HIV-1JR-CSF 
strains to human endometrial (HEC-1) and colorectal (HT-29) CD4-negative epithelial cells, the purified hLF being more 
potent (up to 80%) than the LF-33 peptide. In addition, the hLF, but not the LF-33 peptide, inhibited up to 40% the 
transfer in trans of HIV-1JR-CSF and HIV-1NDK, from immature dendritic cells to CD4 T lymphocytes, likely in a DC-
SIGN-dependent manner. Altogether, these findings demonstrate that hLF can interfere with HIV-1 mucosal transmission 
by blocking virus attachment to epithelial cells and by inhibiting virus transfer from dendritic cells to CD4 T cells, two 
crucial steps of HIV dissemination from mucosae to lymphoid tissue. 
Keywords: Lactoferrin, HIV-1, mucosal transmission. 
1. INTRODUCTION 
  Lactoferrin (LF) is a major iron-binding protein of innate 
immunity against microbial infections, abundantly present in 
mucosal secretions [1]. An exposed site containing 33 
residues (LF-33-GRRRRSVQWCAVSQPEATKCFQWQR 
NMRKVRGP) constitutes the glycosaminoglycans 
recognizing site of the human LF (hLF), whose first six N-
terminus residues are critical for its anti-endotoxin activity 
[2]. Human LF has also been shown to exhibit potent 
antiviral activity in vitro against a wide range of viruses, 
including human immunodeficiency virus type 1 (HIV-1) [3-
5]. The inhibitory activities of hLF against HIV-1 take place 
in early steps of infection, probably during adsorption of the 
virus to target cells [6]. The presence of two mutations in 
HIV-1  env gene in bovine LF-resistant HIV-1 variants 
further suggests that LF targets the HIV-1 entry process [7]. 
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  Following sexual transmission, epithelial cells, immature 
dendritic cells (iDC) present in the mucosa tissue, together 
with CD4 T lymphocytes, are the first cells to encounter the 
virus [8]. Infectious HIV-1 particles that are not sequestrated 
at apical surface of epithelial cells are captured by iDC and 
transported to the draining lymph nodes where the virus is 
efficiently transfered to CD4 T cells. In the initial phase, 
HIV-1 interacts with receptors expressed on iDC such as C-
type lectin receptors (CLR). The dendritic cell-specific 
intercellular adhesion molecule-3-grabbing non-integrin 
(DC-SIGN) molecule plays a crucial role in binding HIV-1 
through the gp120/41 envelope and in transmitting HIV-1 to 
target cells [9]. Recently, we demonstrated that hLF limited 
specifically the adsorption of R5- and X4- tropic free HIV-1 
particles on endometrial HEC-1 epithelial cells by inhibiting 
virus adsorption on heparin-sulfated proteoglycans [10]. 
Furthermore, hLF was shown to strongly bind to DC-SIGN 
on dendritic cells, and prevent HIV-1 capture and 
transmission to CD4 T cells [11]. The region of the hLF 
involved in these mechanisms remains still to be clarified. 
  The aim of the present study was to evaluate whether 
hLF and its exposed domain LF-33 involved in LF-HIV gag 
binding and endotoxines neutralization, may inhibit early 
steps of HIV mucosal transmission, including HIV-1 28    The Open Virology Journal, 2011, Volume 5  Carthagena et al. 
attachment to epithelial and dendritic cells, and HIV-1 
transfer from iDC to CD4 T lymphocytes. 
2. MATERIALS AND METHODOLOGY 
2.1. Reagents and Antibodies 
  The hLF purified from human breastmilk was purchased 
from Sigma Aldrich (St Louis, Montana, USA); the Oregon 
Green 488 fluorescence conjugated lactoferrin from 
Molecular Probes (Oregon Green 488 fluorescence, 
Molecular probes, Belgium); the cytokines GM-CSF, IL-4, 
IL-2, the fluochrome-conjugated directed against CD4, 
CD1a, DC-SIGN, CD86, CD83, CXCR4 and CCR5, from 
R&D (R&D system, Oxon, UK) and BD Pharmingen (Le 
pont de Claix, France); the goat anti-rabbit-FITC from 
Jackson Immunoresearch, USA. The peptide LF-33 
GRRRSVQWCAVSQPEATKCFQWQRNMRKVRGP was 
synthesized by Sequentia (SA, Evry, France). The [342-
371]-DC-SIGN peptide YWNRGEPNNVGEEDCAEFSGN 
GWNDDKCNL, which corresponds to the carbohydrate 
recognition domain (CRD), was synthesized by Sigma 
Aldrich. Polyclonal anti-gp160 IgG were purified from a 
pool of sera sampled from HIV-1-infected patients (labora-
toire de virologie, Hôpital Européen Georges Pompidou, 
Paris, France). The concentrations of hLF and LF-33 peptide 
in μg/ml correspond to 12.8 nM and 250 nM, respectively. 
2.2. Cells 
  The human colorectal epithelial cells line HT-29, and 
endometrial cells HEC-1A were provided by the American
 
Type Culture Collection, Manassas, VA (ATCC HTB-38). 
Cells were grown in RPMI 1640 medium complemented 
with 10% fetal calf serum (FCS), penicillin (100 IU/ml) and 
streptomycin (100 g/ml). The HT-29 cells were CD4
-, DC-
SIGN
-, CXCR4
high+, CCR5
low+ and GalCer
high+, and the HEC-
1 cells were CD4
-, DC-SIGN
-, CXCR4
high+, CCR5
-, GalCer
 
high+ (not shown). Choice of cells were an intestinal cell line 
(HT-29) and an endometrial cell line (HEC-1), 
corresponding to two mucosal tissue largely involved in HIV 
acquisition in exposed people (intestinal and genital 
mucosae). 
  Peripheral blood mononuclear cells (PBMC) were 
isolated from cytapheresis of healthy adult donors by Ficoll 
density gradient centrifugation on medium for separate of 
lymphocytes (Eurobio, Courtaboeuf, France). Purification of 
monocytes was performed using the so-called “roseting” 
technic. In brief, PBMC (10
7/ml) were incubated for 20 min 
in ice with sheep erythrocytes treated with 2-aminoethyli-
sothiouronium bromide (AET) (vol/vol), and subjected to a 
second Ficoll centrifugation. The iDC were obtained by 
culturing monocytes (10
6/ml)
  in RPMI 1640 in heat-
inactivated human serum (10%)
 in plastic culture plates for 1 
h at 37°C. After washing,
 mononuclear adherent cells were 
cultured for 6
  days in RPMI 1640 containing 10% FCS, 
penicillin (100 IU/ml), streptomycin (100 g/ml),
  and IL-
4/GM-CSF (R&D Systems Europe, Abingdon, Oxon, UK) 
both at 10 ng/ml by changing medium every 48 h. 
Autologous lymphocytes (PBL) were obtained from the 
pellet of the second Ficoll centrifugation after lysis of sheep 
erythrocytes (5 min NH4Cl). After washing, PBL were 
cultured in the presence of IL-2 (10 ng/ml) and 
phytohemaglutinin (PHA; 2.5 g/ml) for 48 h at 37°C, 5% 
CO2. After washing, an additional culture was carried out for 
24 h in the presence of IL-2 (10 ng/ml). The purity of iDC 
and T cells was assessed
 by morphological criteria and flow 
cytometry analysis (iDC: 90% or more pure; CD4 T cells: 
85% or more pure). 
2.3. Viral Strains 
 Primary  X4-tropic
 strain HIV-1NDK and R5-tropic strain 
HIV-1JR-CSF were a gift of Prof. F. Barré-Sinoussi (Institut 
Pasteur,
  Paris, France). The HIV-1NDK viral stock was 
obtained by growing virus in IL-2-activated lymphocytes of 
healthy donors. The R5-tropic HIV-1BaL and HIV-1JR-CSF 
were
  amplified in monocyte-derived macrophages cultures. 
Primary strains are thought to be representative of viral 
strains not adapted to their microcellular environment. In 
addition, both monocytotropic (R5-tropic) and 
lymphocytotropic (X4-tropic) HIV-1 strains are present in 
genital secretions, and may participate to HIV mucosal 
crossing in an exposed receptive individual. 
2.4. Flow Cytometry Assessment of hLF Binding to 
Epithelial and Dendritic Cells 
  The constitutive expression of LF by epithelial cells used 
in all experiments and the binding of exogenous hLF were 
analysed by flow cytometry. Briefly, iDC, HEC-1 and HT-
29 cells (10
6 cells) were incubated with polyclonal antibody 
to LF for 30 min at 4°C, and the expression of LF was 
assessed after fixation of cells with 1% paraformaldehyde 
(PFA), by FACSCalibur and the CELL QUEST 
software (Becton Dickinson, New Jersey, USA). To analyse 
the binding of hLF and LF-33 peptide to epithelial cells and 
iDC, 10
6 cells were incubated with the Oregon Green 488 
fluorescence conjugated LF at 10 and 30 g/ml for 1 h in ice. 
Cells were fixed with 1% PFA, and subjected to flow 
cytometry. In order to evaluate possible involvement of the 
LF-33 peptide in the attachment of hLF in some 
experiments, cells were pre-incubated with LF-33 peptide at 
20 g/ml before addition of stained hLF. 
2.5. Modulation of HIV Attachment to Epithelial Cells by 
hLF and LF-33 Peptide 
  To investigate the effect of LF-33 peptide and hLF on 
attachment of HIV-1 particles to epithelial cells, epithelial 
HT-29 and HEC-1 cells (10
6 cells/well) were incubated with 
various quantities of LF-33 peptide or hLF for 30 min at 
room temperature. Afterwards, viral particles from HIV-1BaL, 
HIV-1JR-CSF and HIV-1NDK strains (5 ng of p24 antigen) were 
added on epithelial cells, for 1 h at 37°C. After intensive 
washings (5-fold) with RPMI 1640, cells were lysed by 
addition of 1% Triton in PBS during 15 min at 37°C. Cell 
lysates were centrifuged, and the HIV-1 p24 antigen 
concentration was measured in the supernatant fractions by 
means of immunocapture enzyme-linked immunosorbent 
assay (HIV-1 core profile
 ELISA, DuPont de Nemours, Les 
Ulis, France). 
2.6. Binding of hLF and LF-33 to DC-SIGN 
  The interactions between the HIV-1 glycoprotein gp160, 
the DC-SIGN and the hLF or LF-33 peptide were analysed 
by ELISA. Briefly, a synthetic [342-371]-DC-SIGN peptide 
YWNRGEPNNVGEEDCAEFSGNGWNDDKCNL, correspon-
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was adsorbed on plastic plate (10 g/ml) for 18 h at 4°C. The 
wells were then satured with PBS/skimmed milk (1%) for 2 
h at 37°C. After washing, the DC-SIGN peptide was 
incubated with hLF (100 g/ml) for 18 h at 4°C. The fixed 
LF was detected using hLF-specific antibodies coupled to 
peroxydase (1 g/ml) and streptavidin (1/100, Perkin Elmer, 
Boston, USA). The optical density was meseared at 590 nm 
before ortho-phenylene diamine (OPD) (Pierce, Rockforf, 
USA) addition. 
2.7. Inhibition Experiments of HIV Attachment and 
Transfer by hLF and LF-33 
  The immature phenotype of dendritic cells was checked 
before each experiment by flow cytometry for their 
expression of CD1a, CD83 and CD86, and of HIV-1 
receptors and co-receptors (CD4, CCR5, CXCR4 and DC-
SIGN), using FITC-conjugated anti-CCR5 and CD83 and 
PE-conjugated anti-CD4, CXCR4, DC-SIGN, CD1a and 
CD86 antibodies, for 30 min at 4°C. Cells (10
5  cells/ml) 
were washed in PBS/BSA (0.5%) and fixed in PFA (1%) 
before FACSCalibur and the CELL QUEST software 
analyses. 
  Immature dendritic cells (10
5 cells per essay) were 
incubated with primary R5-tropic HIV-1JR-CSF and with X4-
tropic HIV-1NDK (1 ng/ml of p24 antigen) for 1 h at 37°C. 
For inhibition experiments, cells were incubated with 30 and 
100  g of hLF and LF-33, respectively, before virus 
addition. Cells were then extensively washed, and the p24 
antigen was measured by ELISA after Triton treatment of 
supernatants. 
  Inhibition of HIV-1 transfer in trans to CD4 T 
lymphocytes by hLF and LF-33 peptide was investigated by 
incubation of cells with hLF and LF-33 before addition of 
virus. Cells were then washed, and IL-2- and PHA- activated 
autologous CD4 T lymphocytes (5x10
6 cells) were added, 
and the p24 antigen was measured at 3 days of co-culture. 
Fig. (1). Binding of hLF to epithelial HEC-1 and HT-29 cells. (A): Lack of constitutive expression of LF at cellular surface of epithelial 
cells. Cells were incubated with anti-lactoferrin for 30 min at 4°C, washed and incubated with Oregon-fluorescent-conjugated anti-rabbit for 
additional 30 min at 4°C. Cells were then fixed by PFA (1%) and analysed by FACScalibur analysis. One representative of 4 ruled out 
independent experiments is shown. (B): Human LF binds to HEC-1 and HT-29. Epithelial cells were incubated with fluorescent hLF at 10 
and 30 g (e.g. 128 and 384 nM) for 1 h at 4°C, fixed and analysed by FACScalibur. The corresponding percentages of positive cells and 
mean fluorescences are mentioned in the correspond quadrant. Data are from a typical experiment representative of four independent 
experiments. (C): The mean ± SD of LF positive cells and corresponding mean MFI calculated from 4 experiments is presented. 
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2.8. Statistical Analyses 
  The non parametric Wilcoxon signed-rank and 
Friedman’s tests were used for statistical analyses. 
3. RESULTS 
3.1. Inhibition of HIV-1 Attachment to Epithelial Cells by 
hLF and LF-33 Peptide 
  We investigated whether hLF and LF-33 peptide were 
capable to inhibit attachment of free R5-tropic HIV-1BaL and 
HIV-1JR-CSF, and X4-tropic HIV-1NDK strains to HT-29 and 
HEC-1 epithelial cells. We first determined the LF baseline 
expression by epithelial cells. A neglected percent of 
epithelial cells expressed hLF, 0.6 and 0.8%, respectively 
(Fig. 1A). 
  The HT-29 and HEC-1 cells were incubated with hLF 
conjugated to the Oregon Green 488 fluorochrome (10 g 
and 30 g), fixed and analysed by flow cytometry. The hLF 
binding to HEC-1 cells was at 17% (MFI 56) and 30% (MFI 
70) when used at 10 g and 30 g, respectively. The hLF 
binding to the HT-29 cells was at 82% (MFI 27) and at 96% 
(MFI 50) when used at 10 g and 30 g/ml, respectively 
(Fig. 1B, C). 
  In order to evaluate whether the exposed LF-33 domain 
may be involved in hLF attachment to cells, competition 
experiments between fluorescent hLF and unconjugated-
fluorochrome (used as control) or LF-33 peptide were 
carried out. The epithelial cells were pre-incubated with LF-
33 peptide (or the cold lactoferrin), then washed and 
incubated with the fluorescent hLF. Attachment of hLF was 
determined by flow cytometry. Results of these experiments 
were analysed at two levels, according to the affinity of LF 
binding on epithelial cells. Thus, M1 gate allowed to 
estimate all cells binding hLF, while M2 gate was specific of 
the cells binding hLF with high affinity (stronger signal) 
(Fig.  2). M1 and M2 gates were defined function of the 
fluorescent hLF alone control dot. As expected, a decrease of 
conjugated hLF attachment was observed when cells were 
pre-incubated with cold LF (Fig. 2). Interestingly, the 
competition with LF-33 peptide experiment revealed an 
inhibition of hLF binding on HEC-1 and HT-29. Indeed, pre-
incubation of the peptide was associated with a decreased 
total hLF binding, from 50% to 40% on HEC-1 cells, and 
from 43% to 17% on HT-29 cells (Fig. 2). The competitor 
effect of LF-33 peptide were mainly observed on cell 
binding hLf with high affinity (Gate M2), since there was 
decrease from 10% to 3%, and from 33% to 4% of the LF 
binding on HEC-1 and HT-29, respectively. Moreover, LF-
33 peptide inhibited more efficiently the hLF binding on HT-
29 than HEC-1 (Fig. 2). These results indicate that the LF-33 
peptide binds on epithelial cells with a high affinity, and also 
on hLF cell membrane receptors. 
  We further investigated whether hLF and LF-33 peptide 
were able to inhibit the attachment of free R5-tropic HIV-
1JR-CSF and X4-tropic HIV-1NDK particles to HT-29 and HEC-
1 epithelial cells. Cells were incubated with viruses in the 
presence of hLF and LF-33 peptide for 1 h at 37°C. Under 
these experimental conditions, we assume that internalisation 
of HIV particles via  alternative receptor in CD4-negative 
epithelial cells can be considered as negligible. Cells were 
then washed and HIV-1 p24 antigen was measured. Pre-
Fig. (2). Competition of hLF binding to epithelial cells by the LF-33 peptide. HEC-1 and HT-29 cells were incubated with hLF (20 g or 
256 nM) or LF-33 peptide (20 g or 5 μM) for 30 min at 4°C, washed to eliminate the hLF and peptide excess before to be incubated with 
fluorescent-hLF (20 g) for 1 h at 4°C and analysed by flow cytometry. Histograms depict the mean ± SD of binding (%) and mean 
fluorescences calculated on M2 gate obtained from 3 independent experiments. 
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incubation of cells with human LF at 10 g, 30 g and 60 
g, leads to a decrease of 38%, 56% and 76% of the 
attachment of HIV-1JR-CSF (non parametric Friedman’s test 
for three paired groups; p<0.01) and of 43%, 58% and 60% 
of the attachment of HIV-1NDK (p<0.03), on HEC-1 cells 
(Fig. 3A), respectively; and of 24%, 47% and 64% of the 
attachment of HIV-1JR-CSF (p<0.01), and of 49%, 70% and 
68% of the attachment of HIV-1NDK (p<0.02), on HT-29 cells 
(Fig.  3B). Irrelevant peptide control used instead LF-33 
showed not effect on virus attachment (not shown). 
  The LF-33 peptide exhibited a lower inhibitory effect on 
HIV-1 attachment to epithelial cells as compared to hLF. 
Indeed, the observed reductions of HIV-1JR-CSF binding on 
HEC-1 cells at 10 g, 30 g and 60 g of LF-33 peptide 
were 28%, 41% and 38% (p<0.04), respectively, and those 
of HIV-1NDK bound on HEC-1 cells were 30%, 27% and 
30% (p<0.05), respectively (Fig. 3C). The decreases of HIV-
1JR-CSF attachment to HT-29 cells at 10 g, 30 g and 60 g 
of LF-33 peptide were of 52%, 52% and 47% (p<0.04), 
respectively, and those of HIV-1NDK attachment on HEC-1 
cells were 39%, 32% and 31% (p<0.05), respectively (Fig. 
3D). 
3.2. Inhibition of HIV-1 Transfer from iDC to T Cells by 
hLF, but Not by LF-33 Peptide 
  The dendritic cells used in all experiments presented an 
immature phenotype as demonstrated by the low expression 
of CD83 and the high expression of CD86 and CD1a; the 
iDC expressed also CD4 (70%), CXCR4 (22%), CCR5 
(10%) and DC-SIGN at 85% (Fig. 4). The incubation of iDC 
with hLF and LF-33 had no effect on the immature 
phenotype (data not shown). The Oregon-conjugated hLF 
used at 10 g and 30 g linked, in a dose-dependent manner, 
to iDC at 21 and 32%, respectively (Fig. 5A). 
  The effect of hLF and LF-33 on the transfer of HIV-1 
from iDC to autologous CD4 T lymphocytes was further 
investigated. Dendritic cells were incubated with HIV-1 and 
hLF or LF-33 peptide before washing and addition of IL2-
 
Fig. (3). Binding inhibition of HIV-1 to epithelial cells by hLF and LF-33 peptide. HEC-1 (A and C) and HT-29 (B and D) cells (10
6 
cells) were incubated with HIV-1JR-CSF and HIV-1NDK particles (5 ng/ml of p24 antigen) for 1 h at 37°C. After washes, adsorbed virus was 
treated by Triton and p24 antigen was measured by ELISA. Cells were pre-incubated with hLF (A and B), LF-33 peptide (C and D) or an 
irrelevant peptide control (not shown) for 30 min at room temperature before virus addition. Results are represented as percentage of the 
control (performed without pre-incubation of cells with hLF or LF-33 peptide), and corresponds to the mean ± SD from 3 independent 
experiments. In experimentations, 10 μg/ml of hLF and LF-33 peptide corresponded to 128 nM and 2.5 μM, respectively. 
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activated T lymphocytes (1/5 ratio). Measurement of HIV-1 
p24 antigen released at 72 h in the co-culture supernatant 
showed that at 30 g and 100 g, the percentages of HIV-
1JR-CSF transfer by hLF were decreased by 56% and 61% 
(non parametric Wilcoxon signed-rank; p<0.01), respectively 
(Fig.  5B); and those of HIV-1NDK transfer were 44% and 
64% (p<0.01), respectively (Fig. 5B). No inhibitory effect 
was observed when the LF-33 peptide was used. 
Unexpectedly, the incubation with the LF-33 peptide 
enhanced 3 to 6 fold the HIV-1 transfer from iDC to 
autologous CD4 T cells (p<0.01 for HIV-1JR-CSF and p <0.02 
for HIV-1NDK), as shown in Fig. (5D), likely because the 
peptide increased the HIV-1 attachment to iDC (p<0.02 for 
HIV-1JR-CSF and p <0.03 for HIV-1NDK), as demonstrated by 
binding inhibition experiments (Fig. 5C). Irrelevant peptide 
control used instead LF-33 showed not effect on virus 
attachment to iDC nor on virus transfer from iDC to T cells 
(not shown). 
  Finally, the interactions between hLF and DC-SIGN 
molecule were assessed by indirect ELISA using for coating 
the synthetic peptide «DC-SIGN 342-371» corresponding to 
CRD domain of DC-SIGN interacting with HIV-1 gp120. 
The ELISA optical densities were 1.36 in the presence of 
DC-SIGN peptide, and only 0.03 in its absence (Fig. 5E), 
demonstrating that hLF binds to the DC-SIGN peptide. 
4. DISCUSSION 
  In the present study, purified hLF inhibited the 
attachment of free HIV-1 to epithelial cells. Indeed, hLF 
inhibited as much as 90% of the attachment of X4- and R5- 
tropic primary HIV-1 to human endometrial HEC-1 and 
colorectal epithelial HT29 cell lines. In addition, the effect of 
hLF on viral attachment on epithelial cells is likely mediated 
by the exposed domain LF-33. Indeed, the peptide LF-33 
also inhibited significantly the attachment of primary X4- 
and R5- tropic HIV-1 to HEC-1 and HT-29 epithelial cells. 
Taken together, these findings demonstrate that the 
inhibitory effect of hLF on HIV attachment on epithelial 
cells previously reported by Saïdi and colleagues [10] is 
associated with the external domain LF-33 peptide. 
  We further evaluated the ability of hLF to inhibit the 
transfer in trans of HIV-1 from iDC to CD4 T lymphocytes, 
which constitute one of the major steps of the rapid 
dissemination of HIV-1 from mucosa to lymphoid tissues 
[12]. In our hands, purified hLF inhibited up to 60% the 
virus transfer to CD4 T lymphocytes, whereas no inhibitory 
effect could be observed when using the LF-33 peptide. By 
comparison, the most neutralizing monoclonal antibody to 
gp120, IgGb12, induced up to 90% HIV-1 inhibition [13]. 
By contrast to hLF, the LF-33 peptide enhanced HIV-1 
transfer from iDC to autologous CD4 T cells. These results 
suggest that the LF-33 exposed domain is not involved in 
hLF-associated inhibition of HIV-1 transfer to CD4 T 
lymphocytes. Since hLF binds to DC-SIGN, one can 
hypothesize that hLF could block the virus transfer to 
lymphocytes by hampering the iDC-PBL interaction. One 
can also speculate that LF-33 increases HIV-1 transfer to 
CD4 T lymphocytes by enhancing the virus binding to iDC. 
  We showed that Oregon fluorescence-conjugated hLF 
was able to bind to epithelial cells in a dose-dependent 
manner reaching 40% of positive cells. The mechanisms by 
which hLF interacts with CD4-negative epithelial cells 
remains speculative. However, although both CD4 and 
coreceptors are essential for HIV-1 entry process, the initial 
association of HIV-1 particles to cells could occur in the 
absence of these receptors. Several observations pointed out 
that the attachment of HIV-1 particles to the cell surface 
occurs through interactions with heparan-sulfate 
 
Fig. (4). Phenotypic characterization of iDC by flow cytométrie. Six days old cultured iDC were incubated with FITC/PE-conjugated 
antibodies or matched isotypes for 30 min at 4°C before PFA 1% fixation and FACScalibur analysis. Data are from a typical experiment 
representative of 4 independent experiments. 
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proteoglycans and with the cell surface-expressed nucleolin 
[14-16], suggesting their possible involvement in HIV-1 
attachment inhibition on epithelial cells by hLF. Thus, LF 
likely could exert its effect at the level of viral adsorption or 
penetration, in accordance with its highest effectiveness 
when administered before or simultaneous with the viral 
inoculum, as it occurs in vivo during breastfeeding and 
sexual transmission of HIV-1 [6]. 
  The role of hLF in HIV-1 mucosal transmission remains 
unknown. The amounts of hLF used in our study (30 and 100 
μg/ml) were largely below physiological concentrations, 
suggesting that the blocking properties of hLF on HIV-1 
attachment, replication or transfer in trans, could likely 
modulate the efficiency of HIV acquisition through mucosal 
routes. However, reported observations about hLF levels in 
saliva and breast milk from HIV-1-infected individuals 
remain conflicting. Thus, both increases [17-19] and 
decreases [20, 21] in LF levels were reported. Although a 
linear correlation between low LF serum levels in HIV-
infected pregnant women and perinatal transmission of HIV-
1 to the neonate has been reported [22], no correlation could 
be found between the level of breast milk hLF in HIV-
Fig. (5). Inhibition of HIV-1 transfer from iDC to CD4 T lymphocytes by hLF, not LF-33 peptide. (A) hLF binding to iDC. Cells (10
6 
cells) were incubated with Oregon-conjugated hLF (10 and 30 g, e.g. 128 and 384 nM) for 1 h at 4°C and analysed by FACScalibur. Data 
are from a typical experiment representative of four independent experiments. Histograms depict the mean ± SD of binding (%) and mean 
fluorescences obtained from 4 independent experiments. (B) Effect of hLF on HIV transfer from iDC to CD4 T lymphocytes. iDC were 
incubated or not with purified hLF (30 and 100 g, e.g. 384 and 1280 nM) before addition of HIV-1 for 1 h. Cells were washed and co-
cultured for 3 days with autologous CD4 T lymphocytes. HIV p24 antigen was measured in supernatants by ELISA at day 3. Results are 
represented as percentage of the control (performed without pre-incubation of cells with hLF), and is the mean of transfer ± SD from 3 
independent experiments. (C) Effect of LF-33 peptide on HIV-1 attachment to iDC. iDC were incubated with virus (5 ng/ml of p24 antigen 
of HIV-1JR-CSF and HIV-1NDK) for 1 h at 37°C. After several washes, cells were lysed and HIV p24 antigen was measured by ELISA. Cells 
were pre-incubated with the LF-33 peptide at 30 g and 100 g/ml (e.g. 7.5 μM and 25 μM) for 30 min at room temperature before virus 
addition. Results are represented as percentage of the control (performed without pre-incubation of cells with LF-33 peptide), and is the 
mean of binding ± SD from 3 independent experiments.As negative control, an irrelevant peptide was used instead LF-33 (not shown). (D) 
Effect of LF-33 peptide on HIV transfer from iDC to T cells. iDC were incubated with virus (5 ng/ml of p24 antigen of HIV-1JR-CSF and HIV-
1NDK) for 1 h at 37°C. After several washes, IL-2-stimulated T cells were added to iDC and co-cultured for 72 h before p24 antigen 
measurement.As assessed by binding inhibition experiment, iDC were pre-incubated with the LF-33 peptide at 30 g and 100 g/ml (e.g. 7.5 
μM and 25 μM) for 30 min at room temperature before virus addition. Results are represented as percentage of the control (performed 
without pre-incubation of cells with LF-33 peptide), and is the mean of transfer ± SD from 3 independent experiments. As negative control, 
an irrelevant peptide was used instead LF-33 (not shown). (E) Binding of LF to DC-SIGN. DC-SIGN “342-371” peptide was adsorbed (10 
g/ml) overnight at 4°C. Wells of ELISA plate were satured using PBS/1% powder milk for 2 h at 37°C before addition of purified hLF at 
100 g/ml overnight at 4°C. The fixed hLF was detected by peroxydase-conjugated polyclonal antibody to hLF (1 g/ml). As a control, the 
same experiment was performed in parallel without DC-SIGN “342-371” peptide adsorption. 
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infected breastfeeding mothers and the transmission of virus 
to their children [18]. Finally, the presence of natural 
antibodies to hLF present in mucosal secretions may 
modulate the HIV-inhibitory activity of hLF [10]. 
5. CONCLUSION 
  1. Taken together, our observations demonstrate that hLF 
may interfere with HIV-1 mucosal transmission by blocking 
virus attachment to epithelial cells and by inhibiting virus 
transfer from iDC to CD4 T lymphocytes, two crucial steps 
of HIV dissemination from mucosae to lymphoid tissue. 
  2. The differential effects of the LF-33 peptide on HIV 
attachment and HIV transfer suggest that hLF-mediated 
inhibition of early steps of HIV mucosal crossing may use 
two different pathways. 
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